RBC Capital upgraded Hologic (HOLX) to Outperform from Sector Perform with a price target of $87, up from $72. The firm thinks fiscal 2026 will be the start of a period of mid-single-digit revenue growth for Hologic, leading to a multiple re-rating for the shares. The company’s fiscal 2026 outlook will exceed current Street estimates, driving a period of multiple expansion, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic price target raised to $69 from $65 at Morgan Stanley
- Hologic’s Hold Rating: Balancing Molecular Diagnostics Growth with Breast Health Challenges and External Headwinds
- Hologic’s Earnings Call: Strong Q3 Performance and Optimism
- Hologic price target raised to $75 from $70 at Mizuho
- Hologic’s Mixed Financial Outlook: Hold Rating Amid Growth Concerns and Margin Declines